'Going big': Merck launches frontline PhIII lung cancer study for Keytruda/Yervoy combo
Merck took a dominant position in frontline lung cancer with the approval of a combination of Keytruda and chemo. And it isn’t just waiting around to see if any combination of a PD-(L)1 with a CTLA4 can come along and knock it off its market-leading perch.
The pharma giant has launched a Phase III study combining its checkpoint star with the Bristol-Myers drug. Researchers are recruiting 548 patients at sites around the world, according to the listing at clinicaltrials.gov.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.